Evan Lippman

Executive VP, Business Development at Teva Pharmaceuticals

Speaker

Evan Lippman is Executive Vice President of Business Development at Teva Pharmaceuticals, where he leads the company’s global business development, licensing, and alliance management activities. Since joining Teva in March 2025, he has focused on advancing the company’s growth strategy by building strategic partnerships that expand the pipeline and bring innovative therapies to patients worldwide.

Evan brings more than two decades of experience across corporate development, finance, and operational leadership in both large pharmaceutical companies and emerging biotechnology firms. Over the course of his career, he has led and negotiated more than $100 billion in transactions spanning M&A, licensing, strategic collaborations, divestments, and structured financings.

Prior to joining Teva, he served as Chief Corporate Development & Strategy Officer at Alnylam Pharmaceuticals, where he led global strategy and external innovation efforts, including partnerships, investments, and strategic transactions. Earlier in his career, Evan served as President and Chief Operating Officer of Intima Bioscience and as Senior Vice President and Head of Corporate Development, M&A and Valuation at Takeda Pharmaceutical Company, where he led acquisitions, divestments, licensing deals, and strategic collaborations.

His leadership experience also includes serving as Chief Business & Financial Officer at Aileron Therapeutics and senior roles at EMD Serono, AstraZeneca, and Pfizer.

Evan began his career in investment banking advising companies on mergers, acquisitions, and capital markets transactions. He holds an MBA from Cornell University.